Group 4G: Metastatic Breast Cancer; ER+; Treatment Resistance; Basic Science; Tumor Microenvironment

Poster #P1-03-20: Role of MCM2 and the licensing complex in predicting endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer

Poster #P3-04-18: An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer